Slide
Securing
Connections
Corporate Profile
We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, fosgonimeton (ATH-1017), a novel small molecule, for Alzheimer’s, Parkinson's disease dementia and dementia with Lewy bodies.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Latest Presentations
January 9, 2023
December 7, 2022
Press Releases
January 5, 2023
December 21, 2022
Events & Presentations
December 7, 2022 at 2:00 PM EST
November 16, 2022 at 4:45 PM EST
October 17, 2022 at 8:30 AM EDT